Brief: Arbutus Biopharma Says FDA Indicated They Will Provide An Official Clinical Hold Letter To Arbutus Within 30 Days

Arbutus Biopharma

25/04/2023 13:45

April 25 (Reuters) - Arbutus Biopharma Corp  ABUS.O :
    * ARBUTUS ANNOUNCES FDA CLINICAL HOLD ON IND APPLICATION FOR
AB-101, AN ORAL PD-L1 INHIBITOR
    * ARBUTUS BIOPHARMA CORP: FDA INDICATED THEY WILL PROVIDE AN
OFFICIAL CLINICAL HOLD LETTER TO ARBUTUS WITHIN 30 DAYS
    * ARBUTUS BIOPHARMA CORP: NO LONGER INTENDS TO REPORT
INITIAL DATA
FROM SINGLE-ASCENDING DOSE PORTION OF PHASE 1 CLINICAL TRIAL IN
SECOND HALF OF 2023
    * ARBUTUS BIOPHARMA CORP - FDA INDICATED THEY WILL PROVIDE
AN
OFFICIAL CLINICAL HOLD LETTER TO ARBUTUS WITHIN 30 DAYS

Source text for Eikon:  ID:nGNX980nZN 
Further company coverage:  ABUS.O 

 ((Reutersbriefs@thomsonreuters.com;))